An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing's Syndrome and Autonomous Cortisol Secretion.

Satoko OdaKenji AshidaMakiko UchiyamaShohei SakamotoNao HasuzawaAyako NagayamaLixiang WangHiromi NagataRyuichi SakamotoJunji KishimotoKoji TodakaYoshihiro OgawaYoichi NakanishiMasatoshi Nomura

Published in: The Journal of clinical endocrinology and metabolism (2021)

S-707106 is an effective insulin sensitizer and antisarcopenic and antiobesity medication for these patients.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
type diabetes
chronic kidney disease
peritoneal dialysis
healthcare
emergency department
study protocol
patient reported outcomes
metabolic syndrome
open label
glycemic control
double blind
patient reported